VentiRx Pharma completes enrolment in Phase II study of ovarian cancer drug
US-based VentiRx Pharmaceuticals has announced the completion of patient enrollment in GOG-3003, a Phase II study of VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallo…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Ovarian Cancer | Ovaries | Pharmaceuticals | Study